492P - Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australia...

Date 08 October 2016
Event ESMO 2016 Congress
Session Poster Display
Topics Colon and Rectal Cancer
Presenter Adeola Ayoola
Citation Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370
Authors A. Ayoola1, S. Vantandoust1, A. Roy2, T.J. Price3, M. Kitchener4, D. Roder5, S. Quinn6, G. Kichenadasse7, C. Piantadosi8, R. Padbury9, C. Karapetis2
  • 1Department Of Medical Oncology, Flinders Medical Center, 5042 - Bedford Park/AU
  • 2Medical Oncology, Flinders Medical Centre and Flinders University, Adelaide/AU
  • 3Haematology And Oncology, The Queen Elizabeth Hospital and University of Adelaide, 5011 - Adelaide/AU
  • 4Department Of Nuclear Medicine, The Queen Elizabeth Hospital, 5011 - Adelaide/AU
  • 5Population Health, University of South Australia, Adelaide/AU
  • 6School Of Medicine, Flinders University, 5042 - Adelaide/AU
  • 7Medical Oncology, Flinders Medical Centre and Flinders University, 5042 - Adelaide/AU
  • 8Flinders Center For Innovation In Cancer, Flinders University, 5042 - Adelaide/AU
  • 9Department Of Surgery, Flinders Medical Centre and Flinders University, Adelaide/AU



Colorectal cancer remains one of the commonly diagnosed cancers. The liver is the most common site of metastatic disease and the majority of patients eventually die from cancer progression in the liver. We report on the South Australian experience of the use of liver directed treatment with SIRT and we analyze the safety and efficacy of this intervention.


Data was obtained from the State-wide Metastatic Colorectal Cancer Registry which was established in 2006. Patients treated with SIRT were identified. The objectives were to determine time to progression in the liver, overall survival, response rate, acute toxicity and safety of SIRT. 55 patients (37 males; 18 Females) were treated with SIRT from 2006-2015. The median age was 67.5 years. 70% had ECOG score 


The median time to hepatic progression was 3.72 (95% CI. 2.26-4.83) months; the median survival was 10.6 (95% CI. 7.73-15.32) months. Patients with liver limited disease vs extra-hepatic disease showed no difference in median survival (14.2 vs 10.6months, p = 0.67). In other univariable analyses, there was no significant difference in survival according to age, ECOG, lines of chemotherapy, number of liver lesions or presence of extra-hepatic disease. The radiological response rate was 14.2%. There was no grade 3 or 4 acute toxicity. The most common short-term adverse effects were hepatic pain (18%), nausea, vomiting and back pain. Data regarding potential long term toxicity was not systemically collected.


In this population based analysis, SIRT was mostly administered in pre-treated patients and we observed activity with an acceptable short term safety profile.

Clinical trial identification

Not applicable

Legal entity responsible for the study





All authors have declared no conflicts of interest.